JP2005507897A5 - - Google Patents

Download PDF

Info

Publication number
JP2005507897A5
JP2005507897A5 JP2003532038A JP2003532038A JP2005507897A5 JP 2005507897 A5 JP2005507897 A5 JP 2005507897A5 JP 2003532038 A JP2003532038 A JP 2003532038A JP 2003532038 A JP2003532038 A JP 2003532038A JP 2005507897 A5 JP2005507897 A5 JP 2005507897A5
Authority
JP
Japan
Prior art keywords
silicon dioxide
colloidal silicon
composition
pharmaceutical composition
macrolide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003532038A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005507897A (ja
Filing date
Publication date
Priority claimed from GBGB0123400.4A external-priority patent/GB0123400D0/en
Application filed filed Critical
Publication of JP2005507897A publication Critical patent/JP2005507897A/ja
Publication of JP2005507897A5 publication Critical patent/JP2005507897A5/ja
Withdrawn legal-status Critical Current

Links

JP2003532038A 2001-09-28 2002-09-27 コロイド状二酸化ケイ素を含んでなる医薬組成物 Withdrawn JP2005507897A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0123400.4A GB0123400D0 (en) 2001-09-28 2001-09-28 Organic compounds
PCT/EP2002/010890 WO2003028705A1 (en) 2001-09-28 2002-09-27 Pharmaceutical compositions comprising colloidal silicon dioxide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008309431A Division JP5160386B2 (ja) 2001-09-28 2008-12-04 コロイド状二酸化ケイ素を含んでなる医薬組成物

Publications (2)

Publication Number Publication Date
JP2005507897A JP2005507897A (ja) 2005-03-24
JP2005507897A5 true JP2005507897A5 (https=) 2005-12-15

Family

ID=9922916

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003532038A Withdrawn JP2005507897A (ja) 2001-09-28 2002-09-27 コロイド状二酸化ケイ素を含んでなる医薬組成物
JP2008309431A Expired - Lifetime JP5160386B2 (ja) 2001-09-28 2008-12-04 コロイド状二酸化ケイ素を含んでなる医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008309431A Expired - Lifetime JP5160386B2 (ja) 2001-09-28 2008-12-04 コロイド状二酸化ケイ素を含んでなる医薬組成物

Country Status (30)

Country Link
US (4) US20040254210A1 (https=)
EP (2) EP1432408B8 (https=)
JP (2) JP2005507897A (https=)
KR (1) KR100626785B1 (https=)
CN (3) CN1951390B (https=)
AR (2) AR036643A1 (https=)
AT (1) ATE485813T1 (https=)
BR (2) BRPI0212922B1 (https=)
CA (1) CA2458455C (https=)
CO (1) CO5390072A1 (https=)
CY (2) CY1111119T1 (https=)
DE (1) DE60238131D1 (https=)
DK (2) DK1432408T3 (https=)
EC (1) ECSP024323A (https=)
ES (2) ES2560106T3 (https=)
GB (1) GB0123400D0 (https=)
HU (1) HU229991B1 (https=)
IL (2) IL160498A0 (https=)
MX (1) MXPA04002814A (https=)
MY (1) MY150060A (https=)
NO (1) NO333892B1 (https=)
NZ (2) NZ542273A (https=)
PE (1) PE20030602A1 (https=)
PL (1) PL209704B1 (https=)
PT (2) PT2193788E (https=)
RU (1) RU2322970C2 (https=)
SI (1) SI1432408T1 (https=)
TW (1) TWI242449B (https=)
WO (1) WO2003028705A1 (https=)
ZA (1) ZA200401300B (https=)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
JP4547911B2 (ja) 2002-02-01 2010-09-22 アリアド・ファーマシューティカルズ・インコーポレイテッド リン含有化合物およびその用途
DE60324609D1 (de) * 2002-09-17 2008-12-18 Wyeth Corp GRANULIERTE FORMULIERUNG DES RAPAMYCINESTERS CCl-779
EP1568381A1 (en) * 2002-10-09 2005-08-31 Kyowa Hakko Kogyo Co., Ltd. Remedy for hormone-dependent cancer
DE10351448A1 (de) * 2003-11-04 2005-06-09 Bayer Healthcare Ag Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften
JP5427409B2 (ja) * 2005-06-09 2014-02-26 ハンサ メディカル アクチボラゲット 自己免疫疾患及び移植片拒絶反応を治療するためのＩｄｅＳプロテイナーゼ（化膿連鎖球菌由来）の使用
CN103330694A (zh) * 2006-11-14 2013-10-02 阿里亚德医药股份有限公司 口服制剂
PL3150586T3 (pl) 2007-02-23 2020-06-01 Gilead Sciences, Inc. Modulatory farmakokinetycznych właściwości środków terapeutycznych
HRP20151357T1 (hr) 2008-05-02 2016-01-29 Gilead Sciences, Inc. Upotreba äśestica äśvrstog nosaäśa kako bi se poboljšala procesabilnost farmaceutskog agensa
CN101444494B (zh) * 2008-12-31 2011-03-30 江苏大学 难溶性药物高效长效缓释制剂及其制法
CN101444503B (zh) * 2008-12-31 2011-02-02 江苏大学 一种水飞蓟宾高效长效制剂及其制法
CN101439025B (zh) * 2008-12-31 2011-05-11 江苏大学 一种水飞蓟素高效长效制剂及其制法
PT2389070E (pt) * 2009-01-21 2013-10-21 Mylan Inc Formulações desintegráveis de carbonato de lantânio
US8728516B2 (en) 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
TWI532484B (zh) * 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
TWI540132B (zh) * 2009-06-08 2016-07-01 亞培公司 Ｂｃｌ-２族群抑制劑之口服醫藥劑型
SG10201500152UA (en) 2009-12-22 2015-03-30 Abbvie Inc Abt-263 capsule
US20170087134A1 (en) * 2010-07-12 2017-03-30 Salix Pharmaceuticals, Ltd Formulations of rifaximin and uses thereof
US8709419B2 (en) 2010-08-17 2014-04-29 Hoffmann-La Roche, Inc. Combination therapy
US20120045433A1 (en) * 2010-08-17 2012-02-23 Kapil Dhingra Combination therapy
CA3152557A1 (en) 2010-10-29 2012-05-03 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
TWI620736B (zh) 2010-11-23 2018-04-11 艾伯維巴哈馬有限公司 使用選擇性ｂｃｌ-２抑制劑之治療方法
PT2643322T (pt) 2010-11-23 2017-11-13 Abbvie Inc Sais e formas cristalinas de um agente indutor de apoptose
US9295669B2 (en) 2010-12-14 2016-03-29 Hoffman La-Roche Inc. Combination therapy for proliferative disorders
DE102011052396A1 (de) * 2011-08-04 2013-02-07 Gelita Ag Verfahren zur Herstellung einer stabilen Dispersion von Nanopartikeln, hergestellte Dispersion und deren Verwendung
KR101151890B1 (ko) * 2011-08-11 2012-05-31 동아제약주식회사 안정화 및 가용화된 시롤리무스 유도체 조성물의 제조방법
JP6368242B2 (ja) 2011-10-06 2018-08-01 ノバルティス アーゲー ４０−ｏ−（２−ヒドロキシ）エチル−ラパマイシンを含む医薬組成物
CN102793673A (zh) * 2012-09-07 2012-11-28 中国药科大学 一种小檗碱磷脂复合物固体分散体及其制备方法
WO2014117035A1 (en) 2013-01-24 2014-07-31 Transderm, Inc. COMPOSITIONS FOR TRANSDERMAL DELIVERY OF mTOR INHIBITORS
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
TW201503912A (zh) 2013-03-19 2015-02-01 Novartis Ag 包含癌莫事（ｅｖｅｒｏｌｉｍｕｓ）之醫藥組合物
CN105899232A (zh) 2013-11-13 2016-08-24 诺华股份有限公司 用于增强免疫应答的mTOR抑制剂
CN103610646B (zh) * 2013-12-05 2015-07-15 江苏奥赛康药业股份有限公司 一种含依维莫司的组合物及其制备方法和含有这一组合物的药物制剂
US10287354B2 (en) 2013-12-20 2019-05-14 Novartis Ag Regulatable chimeric antigen receptor
WO2016014530A1 (en) 2014-07-21 2016-01-28 Novartis Ag Combinations of low, immune enhancing. doses of mtor inhibitors and cars
WO2016135740A1 (en) 2015-02-23 2016-09-01 Natco Pharma Limited Process for preparing stable oral compositions of everolimus
HK1245095A1 (zh) 2015-05-20 2018-08-24 Novartis Ag 依维莫司(everolimus)与达托里昔布(dactolisib)的医药组合
US10383860B2 (en) 2015-07-28 2019-08-20 Nippon Kayaku Kabushiki Kaisha Pharmaceutical composition comprising rapamycin or derivative thereof, and method for producing the same
JP6855470B2 (ja) * 2016-05-27 2021-04-07 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
PT3518924T (pt) 2016-09-30 2022-10-27 Salix Pharmaceuticals Inc Formas de dispersão sólidas de rifaximina
CN110114070A (zh) 2016-11-23 2019-08-09 诺华公司 使用依维莫司(everolimus)、达托里昔布(dactolisib)或二者增强免疫反应的方法
JP7108631B2 (ja) 2017-01-06 2022-07-28 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物およびその使用方法
CN110831582B (zh) 2017-07-05 2023-08-11 诺华股份有限公司 药物组合物
CN108125918B (zh) * 2018-01-12 2020-06-23 杭州中美华东制药有限公司 依维莫司药物组合物
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
US11000513B2 (en) 2018-07-02 2021-05-11 Palvella Therapeutics, Inc. Anhydrous compositions of mTOR inhibitors and methods of use
CN115666516A (zh) * 2020-06-01 2023-01-31 希尔帕医疗保健有限公司 包括卡培他滨的快速分散药物组合物
WO2022219652A1 (en) * 2021-04-17 2022-10-20 Bdr Pharmaceuticals International Private Limited Novel sublingual pharmaceutical formulations for everolimus
CN119523923A (zh) * 2024-11-21 2025-02-28 华中药业股份有限公司 一种左炔诺孕酮片及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8608080D0 (en) 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
US5211958A (en) * 1987-11-30 1993-05-18 Gist-Brocades, N.V. Pharmaceutical composition and process for its preparation
US4920102A (en) 1988-04-18 1990-04-24 Eli Lilly And Company Method for treating gastrointestinal disorders
IT1246383B (it) * 1990-04-17 1994-11-18 Eurand Int Metodo per il mascheramento del sapore di farmaci
SK281920B6 (sk) 1991-07-03 2001-09-11 Pharmacia And Upjohn Company Farmaceutická tableta na báze ionexových živíc a spôsob jej výroby
US5605889A (en) 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
PE52896A1 (es) 1994-10-26 1996-12-12 Novartis Ag Composicion farmaceutica
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
DE19544507B4 (de) 1995-11-29 2007-11-15 Novartis Ag Cyclosporin enthaltende Präparate
PT1166651E (pt) * 1996-02-29 2005-04-29 Fujisawa Pharmaceutical Co Granulos de desintegracao rapida de um edulcorante sintetico contendo acido silicico e/ou dioxido de silicio
JP4064476B2 (ja) 1996-03-29 2008-03-19 エラワン ファーマスーティカル リサーチ アンドラボラトリー カンパニー リミテッド 二酸化珪素を有する球状凝集した澱粉
ES2188928T3 (es) * 1996-04-26 2003-07-01 Shionogi & Co Pastilla de liberador-rapido s1452.
GB2318511A (en) 1996-10-23 1998-04-29 Eurand Int Process for the preparation of a pharmaceutical composition for rapid suspension in water
CA2271652A1 (en) 1996-11-12 1998-05-22 Pharmacia & Upjohn Ab Compact member comprising a plurality of porous cellulose matrices, (pcms), method of manufacturing and use thereof
US5989591A (en) 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
US6080427A (en) * 1997-04-17 2000-06-27 Bristol-Myers Squibb Company Cefadroxil monohydrate tablet formulation
PT994697E (pt) 1997-06-13 2005-02-28 Wyeth Corp Formulacoes de rapamicina para administracao oral
DK1064942T3 (da) 1998-03-26 2004-11-01 Fujisawa Pharmaceutical Co Sustained release-fremstilling af et makrolid
FR2785538B1 (fr) * 1998-11-06 2004-04-09 Prographarm Laboratoires Comprime a delitement rapide perfectionne
GB9826656D0 (en) * 1998-12-03 1999-01-27 Novartis Ag Organic compounds
WO2000054752A1 (fr) * 1999-03-15 2000-09-21 Kaken Pharmaceutical Co., Ltd. Comprimes a delitement rapide et procede de fabrication
FR2793690B1 (fr) 1999-03-30 2003-01-03 Cll Pharma Formulations pharmaceutiques en macrolides seuls ou associes a d'autres principes actifs et leur utilisation en therapeutique
AU782005B2 (en) * 1999-05-21 2005-06-30 Kissei Pharmaceutical Co. Ltd. Immediate release medicinal compositions for oral use
GB0008785D0 (en) 2000-04-10 2000-05-31 Novartis Ag Organic compounds
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
US20020076437A1 (en) 2000-04-12 2002-06-20 Sanjeev Kothari Flashmelt oral dosage formulation
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
JP2008531509A (ja) 2005-02-25 2008-08-14 エフ．ホフマン−ラ ロシュ アーゲー 医薬品成分の改良された分散性を有する錠剤
TWI358407B (en) 2005-06-22 2012-02-21 Lundbeck & Co As H Crystalline base of escitalopram and orodispersibl

Similar Documents

Publication Publication Date Title
JP2005507897A5 (https=)
JP2009102341A5 (https=)
CA2458455A1 (en) Pharmaceutical compositions comprising colloidal silicon dioxide
US20200078354A1 (en) Immediate release abuse deterrent tablet
TWI254640B (en) Use of a polymer of acrylic type as a disintegration agent
JP6067100B2 (ja) 即放性乱用抑止医薬組成物
WO2004064752A3 (en) Method of preparing sustained release microparticles
JP5750847B2 (ja) アトルバスタチン経口投与用粒子状医薬組成物
WO2004100857A3 (en) Highly plastic granules for making fast melting tablets
WO2009043844A3 (en) Orodispersible tablets
JP2010518086A5 (https=)
TW200635618A (en) Solid dosage form comprising proton pump inhibitor and suspension made thereof
WO2007008752A3 (en) Sustained release pharmaceutical compositions for highly water soluble drugs
EP2842549A1 (en) Orally disintegrating tablet and method for producing same
JP2009507047A5 (https=)
MX2008000099A (es) Composiciones farmaceuticas de liberacion modificada novedosas, y procedimiento de preparacion de dichas composiciones.
WO2007071581A3 (de) Pharmazeutische formulierung für die herstellung von schnell zerfallenden tabletten
BG108516A (en) Pharmaceutical formulation
WO2003047552A3 (en) Pharmaceutical composition comprising a 5ht1 receptor agonist
HRP20100120T1 (hr) Formulacije s valsartanom
JP2014530802A5 (https=)
CA2502731A1 (en) Sustained release composition for oral administration of drugs
JP2011516544A5 (https=)
GEP20125636B (en) Slow-release formulation based on glycogen and alginate association
WO2005034857A8 (en) Methods and compositions comprising diamines as new anti-tubercular therapeutics